AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery — TRAVERS

Vestibular Vertigo Clinical Trial

Official title:
Multicenter Randomized Controlled Phase 2 Trial to Evaluate AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery (TRAVERS)

Status Completed

Clinical Trial Summary

Treatment of vertigo after removal of a tumor of the balance and hearing nerve after neurosurgery, which damages or cuts the vestibular nerve (balance). This trial explores the efficacy and safety of AM-125 in the treatment of acute vertigo. In this proof of concept trial patients experiencing vertigo after neurosurgery (vestibular schwannoma labyrinthectomy and vestibular neurectomy) will receive AM-125 or placebo. It evaluates the potential of AM-125 versus placebo in reducing the symptoms of vestibular dysfunction and accelerating vestibular compensation following neurosurgery.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03908567
Study type	Interventional
Source	Auris Medical, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	July 18, 2019
Completion date	March 28, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06332326` - Investigation of the Efficacy of Non-Invasive Vagus Nerve Stimulation and Physiotherapy in Unilateral Vestibular Hypofunction Patients	N/A
Not yet recruiting	`NCT03974867` - Vestibular Prognosis Assessment of ISSNHL With Vestibular Dysfunction Treated With Oral or Intratympanic Glucocorticoids	N/A
Recruiting	`NCT05192564` - Exercise and Vestibular Hypofunction	N/A